Table Graph
      published meta-analysis   sensitivity analysis   studies

Immunosuppressants drugs in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] 0.80[0.61; 1.07]COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, NCT04377750 (HMO-0224-20), 0, Rosas (REMDACTA), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202168%1,258moderatenot evaluable deathsdetailed resultsCOV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] DEVENT, 0 0.47 [0.22; 1.00] Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80] sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] 0.85[0.67; 1.09]COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, DEVENT, 0, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NCT04377750 (HMO-0224-20), 0, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 20211116%2,042moderatelow deaths (time to event analysis only)detailed resultsCOVACTA (Rosas), 2020 1.16 [0.73; 1.84] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] 1.03[0.77; 1.38]COVACTA (Rosas), 2020, Rosas (REMDACTA), 202120%1,092moderatenot evaluable clinical improvementdetailed resultsCOV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36] sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.33[1.02; 1.74]COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021718%1,081moderateserious clinical improvement (14-day)detailed resultsCOV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09] 1.97[0.95; 4.09]COV-BARRIER (critically ill), 202210%101NAnot evaluable clinical improvement (28-day)detailed resultsCOV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.33[0.95; 1.87]COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202140%564moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsLescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] 1.09[0.87; 1.35]Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 202120%506moderatenot evaluable death or ventilationdetailed resultsRosas (REMDACTA), 2021 0.98 [0.72; 1.34] sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82] sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44] 0.70[0.41; 1.20]Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0362%919seriousnot evaluable hospital dischargedetailed resultsRosas (REMDACTA), 2021 0.97 [0.79; 1.20] 0.97[0.79; 1.20]Rosas (REMDACTA), 202110%649NAnot evaluable mechanical ventilationdetailed resultsCOVACTA (Rosas), 2020 0.67 [0.39; 1.14] sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71] sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73] Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48] Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07] 0.37[0.20; 0.69]COVACTA (Rosas), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021534%568seriousserious ICU admissiondetailed resultsCOVACTA (Rosas), 2020 0.48 [0.25; 0.94] 0.48[0.25; 0.94]COVACTA (Rosas), 202010%191NAnot evaluable off oxygenationdetailed resultssarilumab phase 2 high dose, 0 1.99 [0.95; 4.15] sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21] 1.46[0.79; 2.68]sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0228%270seriousnot evaluable recoverydetailed resultsCOV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20] 1.57[0.77; 3.20]COV-BARRIER (critically ill), 202210%101NAnot evaluable related AE (TRAE)detailed resultsSingh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93] 1.26[0.14; 11.07]Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202120%25moderatenot evaluable serious adverse eventsdetailed resultsCOVACTA (Rosas), 2020 0.81 [0.54; 1.22] Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] Rosas (REMDACTA), 2021 0.83 [0.59; 1.18] 0.93[0.74; 1.16]COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 202140%1,582moderatenot evaluable adverse eventsdetailed resultsCOVACTA (Rosas), 2020 0.87 [0.52; 1.45] Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] Rosas (REMDACTA), 2021 1.32 [0.92; 1.89] Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71] Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01] 1.09[0.81; 1.46]COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021624%1,607moderateserious0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-03 16:32 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons